Preliminary Findings Point to Low Risk of Secondary Cancers from CAR-T Therapies

CAR T cancer

Pictured: 3D illustration of a CAR-T cell attacking a cancer cell/iStock, Meletios Verras

New research from the University of Pennsylvania and Stanford University finds no link between CAR-T cell therapies and the development of secondary T-cell malignancies.

At a joint event held by the Friends of Cancer Research and Parker Institute for Cancer Immunotherapy on Monday, cell therapy pioneer Carl June of the University of Pennsylvania Perelman School of Medicine revealed findings from a recent unpublished study from his group that looked at 783 patients who had received CAR-T treatments for HIV-1 or various cancers. Over more than 2,200 patient-years of observation, the group found 18 patients, or 2.3%, who developed secondary malignancies.

These secondary cancers arose a median of 1.94 years after CAR-T treatment, and most were solid tumors.

However, June said that none of these cases showed insertion of the CAR…
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks